Showing results (141-150 of 202) with videos related to
Sort By:
Pageof 21
Cancer Research|January 28, 2004
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemiaNicholas J Donato, Ji Y Wu, Jonathan Stapley, et al.British Journal of Haematology|June 29, 2006
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapseFrancis Giles, Srdan Verstovsek, Guillermo Garcia-Manero, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Benjamin Bekele, et al.Blood|July 20, 2002
Myelodysplastic syndrome is not merely "preleukemia"Maher Albitar, Taghi Manshouri, Yu Shen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDavid P Steensma, Maria R Baer, James L Slack, et al.Frontiers in Oncology|March 31, 2025
Next-generation sequencing guides diagnosis and treatment in a complex presentation of ALK-positive anaplastic large-cell lymphoma: a case reportTejasvini Vaid, Thomas S Gunning, Rachel Cohen, et al.Cancer|March 26, 2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaFrancis J Giles, Martin S Tallman, Guillermo Garcia-Manero, et al.Pageof 21